\
&
Contact us
\
&
Contact us
Published on | 2 years ago
ProgrammesPlease note that the following update was published regarding the call topic HORIZON-WIDERA-2024-ERA-01-05: Experimentation and exchange of good practices for value creation.
The Commission is considering to cancel the topic “HORIZON-WIDERA-2024-ERA-01-05: Experimentation and exchange of good practices for value creation”. The next amendment of the Work Programme will propose to re-introduce the topic with an updated description to be funded under a call in 2024.
Source: Funding and Tenders Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Civil Security Digital, Industry & Space Agro-Food, Environment
The European Innovation Council has launched a call to recruit independent experts of diverse innovative defence and dual-use technologies (as eg. maritime, medical, drones, financial expertise, ..). It is important for the EIC to have a solid batch of experts with a balanced national diversity. Note that, as a requirement and due to security sens... read more
Culture and society Climate, Energy, Mobility EIC
OASC (Open & Agile Smart Cities & Communities) is a partner in the ACCEND project, a Europe-wide project building the foundations for a stronger, more connected deep tech scaleup scene. If you're developing solutions for Smart Cities, Net Zero Cities or Regenerative Cites, you might be interested in this opportunity to accelerate your... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
